Loading clinical trials...
Loading clinical trials...
An Open-Label, Randomized Study to Evaluate the Bioequivalence of Selpercatinib Formulations
Conditions
Interventions
Selpercatinib
Locations
4
United States
Anaheim Clinical Trials, LLC
Anaheim, California, United States
LabCorp CRU, Inc.
Daytona Beach, Florida, United States
Covance Dallas
Dallas, Texas, United States
LabCorp CRU, Inc.
Madison, Wisconsin, United States
Start Date
October 29, 2021
Primary Completion Date
July 19, 2022
Completion Date
July 19, 2022
Last Updated
March 17, 2025
NCT00104325
NCT07470866
NCT07221448
NCT07388667
NCT07118891
NCT03878121
Lead Sponsor
Loxo Oncology, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions